New phase 3 data from the investigational therapy IDegLira (insulin degludec [Tresiba®]/liraglutide injection [Victoza®]) were presented at the World Diabetes Congress of the International Diabetes Federation. The DUAL™ II trial shows that in comparison with insulin degludec, IDegLira achieved superior control of blood sugar levels (HbA1cImproved fasting and postprandial plasma glucose levels were seen with IDegLira throughout the day and across meals, while providing significant weight loss for adults with type 2 diabetes uncontrolled on basal insulin.

More...